Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study
The fracture impact of adjuvant bisphosphonates in breast cancer is not defined with most trials reporting changes in bone mineral density as a surrogate. The AZURE trial (ISRCTN79831382) evaluated the impact of adjuvant zoledronic acid (ZOL) on fractures.The AZURE trial is an academic, multi-centre, randomised phase III study evaluating the addition of ZOL 4  mg to standard therapy (neo/adjuvant chemotherapy and/or endocrine therapy) for 5 years (administered by intravenous (iv) infusion every 3–4 weeks for 6 doses, then 3 monthly × 8 and 6 monthly × 5) in patients with stage II/...
Source: European Journal of Cancer - March 12, 2018 Category: Cancer & Oncology Authors: C. Wilson, R. Bell, S. Hinsley, H. Marshall, J. Brown, D. Cameron, D. Dodwell, R. Coleman Tags: Original Research Source Type: research

Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw
Conclusion Replacing ZA with denosumab is a risk factor for developing ONJ. Both bisphosphonate binding to the bone and RANKL inhibition could additively increase the risk of developing ONJ. We bring the replacement of ZA with denosumab to the attention of clinical oncologists. (Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology)
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - March 6, 2018 Category: ENT & OMF Source Type: research

Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxyvitamin d and previous oral bisphosphonate therapy
Endocrine Practice,Volume 24, Issue 5, Page 405-410, May 2018. (Source: Endocrine Practice)
Source: Endocrine Practice - March 2, 2018 Category: Endocrinology Authors: Chiara Crotti Nelson B. Watts Maria De Santis Angela Ceribelli Gianluigi Fabbriciani Francesca Cavaciocchi Bianca Marasini Carlo Selmi Marco Massarotti Source Type: research

1D Co(II) coordination polymers based on cyclobutyl and cyclopentyl-substituted zoledronate analogues: synthesis, structural comparison, thermal stability and magnetic properties
New J. Chem., 2018, Accepted Manuscript DOI: 10.1039/C8NJ00118A, PaperTomasz Rojek, Waldemar Goldeman, Katarzyna Slepokura, Marek Duczmal, Agnieszka Wojciechowska, Ewa Matczak-Jon Two novel derivatives of zoledronic acid: 1-hydroxy-2-[1-(1H-imidazol-1-yl)cyclobutyl]ethylidene-1,1-diphosphonic acid (H4cbtZol) and 1-hydroxy-2-[1-(1H-imidazol-1-yl)cyclopentyl]ethylidene-1,1-diphosphonic acid (H4cptZol) were synthesized, crystallized from water solutions as H4cbtZol ∙H2O (1) and H4cptZol ∙4H2O (2), and characterized by single-crystal X-ray... The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Ne...
Source: RSC - New J. Chem. latest articles - March 1, 2018 Category: Chemistry Authors: Tomasz Rojek Source Type: research

Severe Acute Kidney Injury After Single-Dose Injection of Zoledronic Acid in an Elderly Patient
No abstract available (Source: American Journal of Therapeutics)
Source: American Journal of Therapeutics - March 1, 2018 Category: Drugs & Pharmacology Tags: Letters to the Editor Source Type: research

Negative effect of zoledronic acid on tendon-to-bone healing.
The objective of this study was to evaluate the effect of the bisphosphonate zoledronic acid (ZA) on tendon-to-bone healing. Methods - Wistar rats (n = 92) had their right Achilles tendon cut proximally, pulled through a bone tunnel in the distal tibia and sutured anteriorly. After 1 week animals were randomized to receive a single dose of ZA (0.1 mg/kg IV) or control. Healing was evaluated at 3 and 6 weeks by mechanical testing, dual-energy X-ray absorptiometry and histology including immunohistochemical staining of osteoclasts. Results - ZA treatment resulted in 19% (95% CI 5-33%) lower pullout strength and 43% (9...
Source: Acta Orthopaedica - March 1, 2018 Category: Orthopaedics Authors: Hjorthaug GA, Søreide E, Nordsletten L, Madsen JE, Reinholt FP, Niratisairak S, Dimmen S Tags: Acta Orthop Source Type: research

Negative effect of zoledronic acid on tendon-to-bone healing
Volume 89, Issue 3, June 2018, Page 360-366 . (Source: Acta Orthopaedica)
Source: Acta Orthopaedica - March 1, 2018 Category: Orthopaedics Authors: Geir Aasmund Hjorthaug Endre S øreide Lars Nordsletten Jan Erik Madsen Finn P Reinholt Sanyalak Niratisairak Sigbj ørn Dimmen Source Type: research

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
CONCLUSION: Denosumab's efficacy in delaying or preventing SREs, potential to improve PFS, and lack of renal toxicity makes it a cost-effective option for the prevention of SREs in MM compared with zoledronic acid. PMID: 29480139 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 28, 2018 Category: Health Management Tags: J Med Econ Source Type: research

A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a severe stage of the disease with a number of newly discovered treatment options. These therapeutic alternatives including abiraterone acetate, enzalutamide, cabazitaxel, immunotherapy with sipuleucel-T, radiopharmaceuticals and bone...
Source: Iranian Journal of Pharmaceutical Research - February 28, 2018 Category: Drugs & Pharmacology Source Type: research

Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw
This study evaluated the risks of developing ONJ when replacing ZA with denosumab. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - February 28, 2018 Category: ENT & OMF Authors: Tomoko Higuchi, Yoshihiko Soga, Misato Muro, Makoto Kajizono, Yoshihisa Kitamura, Toshiaki Sendo, Akira Sasaki Tags: Oral Medicine Source Type: research

Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw
This study evaluated the risks of developing ONJ when replacing ZA with denosumab. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - February 28, 2018 Category: ENT & OMF Authors: Tomoko Higuchi, Yoshihiko Soga, Misato Muro, Makoto Kajizono, Yoshihisa Kitamura, Toshiaki Sendo, Akira Sasaki Tags: Oral Medicine Source Type: research

Prevention of ovariectomy-induced osteoporosis in rats : Comparative study of zoledronic acid, parathyroid hormone (1-34) and strontium ranelate.
Abstract Recently, the use of the pharmacological agents strontium ranelate (SR), parathyroid hormone (1-34, PTH) and zoledronic acid (ZA) has come to prominence for the treatment of osteoporosis due to their ability to prevent bone loss in osteoporotic patients. Although much emphasis has been placed on using pharmacological agents for the prevention of disease, much less attention has been placed on which one is more effective. There is still no direct comparative study on these three drugs. The aim of the present study was to investigate the effect of SR, PTH, ZA on preventing ovariectomy-induced osteoporosis i...
Source: Zeitschrift fur Gerontologie und Geriatrie - February 23, 2018 Category: Geriatrics Authors: Tao ZS, Zhou WS, Wu XJ, Zhang X, Wang L, Xie JB, Xu ZJ, Ding GZ, Yang M Tags: Z Gerontol Geriatr Source Type: research

What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
ConclusionsUniquely, we have included all available results and appropriately accounted for inclusion of multi-arm, multi-stage trials in this AD-NMA. Our results support the use of AAP or Doc with ADT in men with metastatic hormone-naive prostate cancer. AAP appears to be the most effective treatment, but it is not clear to what extent and whether this is due to a true increased benefit with AAP or the variable features of the individual trials. To fully account for patient variability across trials, changes in prognosis or treatment effects over time and the potential impact of treatment on progression, a network meta-an...
Source: Annals of Oncology - February 23, 2018 Category: Cancer & Oncology Source Type: research

Beneficial Therapeutic Effects of Sildenafil on Bone Healing in Animals Treated with Bisphosphonate
Conclusions: Sildenafil may have positive effects on accelerating and improving fracture healing, and it may be used as a supporting factor in bone healing in patients treated with bisphosphonate (BP) to prevent negative effects of BP's (Source: Nigerian Journal of Clinical Practice)
Source: Nigerian Journal of Clinical Practice - February 21, 2018 Category: Rural Health Authors: C Bereket I Sener N Cakir- & #214;zkan ME & #214;nger AV Polat Source Type: research

Effectiveness of interventions aimed at improving physical and psychological outcomes of fall-related injuries in people with dementia: a narrative systematic review
ConclusionsDue to high heterogeneity across the studies, definitive conclusions could not be reached. Most post-fall interventions were not aimed at patients with dementia and have shown little efficacy regardless of cognitive status. Minor improvements to some quality of life indicators were shown, but these were generally not statistically significant. Conclusions were also limited due to most studies addressing hip fracture; the interventions provided for this type of injury may not be suitable for other types of fractures or soft tissue injuries, or for use in primary care.Systematic review registrationPROSPEROCRD42016...
Source: Systematic Reviews - February 20, 2018 Category: International Medicine & Public Health Source Type: research

Large-scale expansion of V γ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor–modified effector cells
Publication date: Available online 3 February 2018 Source:Cytotherapy Author(s): Lin Xiao, Can Chen, Zhendong Li, Sumin Zhu, Johan Ck Tay, Xi Zhang, Shijun Zha, Jieming Zeng, Wee Kiat Tan, Xin Liu, Wee Joo Chng, Shu Wang Vγ9Vδ2 T cells are a minor subset of lymphocytes in the peripheral blood that has been extensively investigated for their tolerability, safety and anticancer efficacy. A hindrance to the broad application of these cells for adoptive cellular immunotherapy has been attaining clinically appropriate numbers of Vγ9Vδ2 T cells. Furthermore, Vγ9Vδ2 T cells exist at low freque...
Source: Cytotherapy - February 19, 2018 Category: Cytology Source Type: research

Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat
ConclusionsIn a rat model of BRONJ, microtomography evidenced osteonecrosis in BRONJ. Raman spectroscopy showed an increased mineralization. Vascularization after tooth extraction was impaired by ZA.Clinical relevanceProlonged BP administration caused an increase in the mineralization and a quantitative reduction of the vascularization in the alveolar bone; both factors might be involved concomitantly in the BRONJ pathophysiology. (Source: Clinical Oral Investigations)
Source: Clinical Oral Investigations - February 16, 2018 Category: Dentistry Source Type: research

Effect of zoledronic-acid and alendronate on bone oedema and pain in spontaneous osteonecrosis of the knee: a new paradigm in medical management
Conclusion Our data shows that the combination therapy gives early pain relief and reduction of bone oedema, demonstrating to be and is safe, effective and well-tolerated for a painful disease entity like such as spontaneous osteonecrosis of knee. (Source: Revista Brasileira de Ortopedia)
Source: Revista Brasileira de Ortopedia - February 9, 2018 Category: Orthopaedics Source Type: research

Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker
ConclusionsThis is the first model to predict BMD for up to 2  years following two annual doses of ZOL using patients’ background characteristics and the early response of TRACP-5b. This model allows us to inform patients at the initial stage of ZOL treatment of their predicted response to treatment. (Source: Osteoporosis International)
Source: Osteoporosis International - February 8, 2018 Category: Orthopaedics Source Type: research

[Comment] Denosumab for myeloma bone disease: ready for prime time?
Increased osteoclast activity is the hallmark of myeloma bone disease and RANKL is the most potent osteoclast activator. Bisphosphonates and monoclonal antibodies targeting RANKL (eg, denosumab) inhibit osteoclasts and are the mainstay of therapy of cancer-related bone disease. Bisphosphonates reduce skeletal-related events. Zoledronic acid, a potent bisphosphonate, improved survival compared with clodronate of patients with myeloma in a large study1 that used thalidomide-based or conventional chemotherapy. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Meletios A Dimopoulos, Efstathios Kastritis Tags: Comment Source Type: research

[Articles] Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
In patients with newly diagnosed multiple myeloma, denosumab was non-inferior to zoledronic acid for time to skeletal-related events. The results from this study suggest denosumab could be an additional option for the standard of care for patients with multiple myeloma with bone disease. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher, Kazuyuki Shimizu, Ram ón García-Sanz, Brian Durie, Wojciech Legieć, Marta Krejčí, Kamel Laribi, Li Zhu, Paul Cheng, Douglas Warner, G David Roodman Tags: Articles Source Type: research

Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review
ConclusionsThe presence of diabetes does not alter anti-osteoporotic treatment response, regarding BMD increase and vertebral fracture risk reduction. (Source: Endocrine)
Source: Endocrine - February 6, 2018 Category: Endocrinology Source Type: research

In  vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws
Conclusion Geranylgeraniol in a form of local solution may be a promising option for prevention and treatment of BRONJ. (Source: Journal of Cranio Maxillofacial Surgery)
Source: Journal of Cranio Maxillofacial Surgery - February 6, 2018 Category: ENT & OMF Source Type: research

Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in  vivo.
In conclusion, the present study demonstrated that ZOL significantly increased the sensitivity of breast cancer cells to fulvestrant through inhibition of the ERK/HIF-1α pathway. PMID: 29393454 [PubMed - as supplied by publisher] (Source: Molecular Medicine Reports)
Source: Molecular Medicine Reports - February 4, 2018 Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Effect of Zoledronic Acid and Denosumab in Patients With Low Back Pain and Modic Change: A Proof ‐of‐Principle Trial
ABSTRACT The aim of this study was to evaluate the effect of zoledronic acid (ZA) and denosumab on low back pain (LBP) and Modic change (MC) over 6 months. Adults aged ≥40 years with significant LBP for at least 6 months duration and MC (type 1, 2, or mixed) were randomized to receive ZA (5 mg/100 mL), denosumab (60 mg), or placebo. LBP was measured monthly by visual analogue scale (VAS) and the LBP Rating Scale (RS). MC was measured from MRIs of T12–S1 vertebrae at screening and 6 months. A total of 103 participants with moderate/severe LBP (mean VAS = 57 mm; mean RS&thin...
Source: Journal of Bone and Mineral Research - February 2, 2018 Category: Orthopaedics Authors: Guoqi Cai, Laura L Laslett, Dawn Aitken, Andrew Halliday, Feng Pan, Petr Otahal, Deborah Speden, Tania M Winzenberg, Graeme Jones Tags: Original Article Source Type: research

Effect of Zoledronic Acid and Denosumab in Patients With Low Back Pain and Modic Change: A Proof ‐of‐Principle Trial
Journal of Bone and Mineral Research,Volume 33, Issue 5, Page 773-782, May 2018. (Source: Journal of Bone and Mineral Research)
Source: Journal of Bone and Mineral Research - February 2, 2018 Category: Orthopaedics Authors: Guoqi Cai , Laura L Laslett , Dawn Aitken , Andrew Halliday , Feng Pan , Petr Otahal , Deborah Speden , Tania M Winzenberg , Graeme Jones Source Type: research

Utilization of agents to prevent skeletal-related events among patients with multiple myeloma: analysis of real-world data
ConclusionsThese results highlight the possibility of suboptimal prevention of skeletal-related events due to non-compliant dosing and non-persistence after patients initiate BTA therapy. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - January 25, 2018 Category: Cancer & Oncology Source Type: research

An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer.
Abstract PURPOSE: This observational study of oncologic clinical practices was designed to describe real-world patterns of use of emerging therapies (abiraterone acetate, cabazitaxel, enzalutamide, radium-223, sipuleucel-T) in patients with castration-resistant prostate cancer and to characterize their concomitant use with denosumab or zoledronic acid. METHODS: A retrospective cohort study was conducted using a database of electronic health records from oncology practices across the United States. Eligible patients had a diagnosis of prostate cancer (International Classification of Diseases, Ninth Revision [I...
Source: Clinical Therapeutics - January 24, 2018 Category: Drugs & Pharmacology Authors: Liede A, Wade S, Lethen J, Hernandez RK, Warner D, Abernethy AP, Finelli A Tags: Clin Ther Source Type: research

Skeletal dissemination in Paget ’s disease of the spine
ConclusionsWe outline skeletal dissemination as a possibly surgery-related complication in a patient with PDB in the lumbar spine. Bisphosphonates remain the treatment of first choice in PDB and surgical interventions should be considered very carefully. (Source: European Spine Journal)
Source: European Spine Journal - January 17, 2018 Category: Orthopaedics Source Type: research

Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia
Journal of Orthopaedic Research, EarlyView. (Source: Journal of Orthopaedic Research)
Source: Journal of Orthopaedic Research - January 16, 2018 Category: Orthopaedics Source Type: research

Effect of intravenous zoledronic acid on histopathology and recurrence after extended curettage in giant cell tumors of bone: A comparative prospective study
Conclusions: We observed that bisphosphonates reduce osteoclast activity and affects stromal cells in GCT, resulting in the reduction of their numbers and noticeable apoptosis. This results in better marginalization of the lesions and reduced recurrence. Extended curettage of friable GCT became easier and adequate which otherwise might not have been possible. (Source: Indian Journal of Orthopaedics)
Source: Indian Journal of Orthopaedics - January 10, 2018 Category: Orthopaedics Authors: Zile Singh Kundu Rajeev Sen Ankur Dhiman Pankaj Sharma Ramchander Siwach Parveen Rana Source Type: research

Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer.
CONCLUSION: These results showed that neoadjuvant LET with zoledronic acid could not achieve overall effect for local tumor response. However, patients with a low frequency of γδ T cells would benefit from the treatment including zoledronic acid. (UMIN 000008701). PMID: 29310035 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - January 5, 2018 Category: Cancer & Oncology Authors: Sugie T, Suzuki E, Yamauchi A, Yamagami K, Masuda N, Gondo N, Sumi E, Ikeda T, Tada H, Uozumi R, Kanao S, Tanaka Y, Hamazaki Y, Minato N, Toi M Tags: Breast Source Type: research

Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor ‐1
In this study we aimed to characterize the effect of Zol and IL‐2 on VEGF signalling of blood‐derived immune cells in vitro. Upon stimulation with IL‐2, T cells and natural killer (NK) cells increase production of VEGF consecutively to the release of proinflammatory interferon (IFN)‐γ, and Zol accelerates this response specifically in γδ T cells. VEGF can, in turn, be antagonized by soluble VEGF receptor (sVEGFR)‐1, which is released depending on stimulatory conditions and the presence of monocytes. Additionally, malignant cells represented by leukaemia and lymphoma cell lines produce VEGF and s...
Source: Clinical and Experimental Immunology - January 4, 2018 Category: Allergy & Immunology Authors: T. Hoeres, M. Wilhelm, M. Smetak, E. Holzmann, G. Schulze ‐Tanzil, J. Birkmann Tags: Original Article Source Type: research

Zoledronic acid overcomes chemoresistance by sensitizing cancer stem cells to apoptosis.
Abstract Unlike low tumorigenic bulk tumor cells (non-CSCs), cancer stem cells (CSCs) are a subset of tumor cells that can self-renew and differentiate into different cancer subtypes. CSCs are considered responsible for tumor recurrence, distant metastasis, angiogenesis, and drug or radiation resistance. CSCs also are resistant to apoptosis. Zoledronic acid (ZA) is a third generation bisphosphonate that reduces cell proliferation and exhibits anti-tumor effects by inducing cell death in some malignancies; however, the effects of ZA on CSCs are unclear. We investigated the anti-cancer effects of ZA on two epithelia...
Source: Biotechnic and Histochemistry - January 4, 2018 Category: Research Authors: Rouhrazi H, Turgan N, Oktem G Tags: Biotech Histochem Source Type: research

Effect of zoledronic acid and denosumab in patients with low back pain and Modic change: a proof of principle trial
This article is protected by copyright. All rights reserved (Source: Journal of Bone and Mineral Research)
Source: Journal of Bone and Mineral Research - January 3, 2018 Category: Orthopaedics Authors: Guoqi Cai, Laura L Laslett, Dawn Aitken, Andrew Halliday, Feng Pan, Petr Otahal, Deborah Speden, Tania M Winzenberg, Graeme Jones Tags: Clinical Trial Source Type: research

Therapeutic Approaches to Secondary Fracture Prevention in High Risk Populations: Current Recommendations and Advances
Background: Osteoporotic fragility fracture is a burgeoning health epidemic that is associated with high rates of disability, morbidity, and mortality. Based on NHANES data, approximately 10 million Americans are affected by this disease. Areas of Uncertainty: Successful secondary fracture prevention measures are often limited by the under-diagnosis of osteoporosis after fragility fractures because of lack of patient and physician awareness of the disease, lack of follow-up, and medical nonadherence. Therapeutic Advances: Current guidelines recommend the use of Bisphosphonate as the first-line therapy for secondary...
Source: American Journal of Therapeutics - January 1, 2018 Category: Drugs & Pharmacology Tags: Systematic Review and Clinical Guidelines Source Type: research

Treatment dynamics of bone ‐targeting agents among men with bone metastases from prostate cancer in the United States
ConclusionsBone‐targeting agent therapy is initiated by the majority of men living with bone metastases following a prostate cancer diagnosis; however, the timing of initiation is highly variable. Once on treatment, gaps or interruptions in therapy are common. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - January 1, 2018 Category: Drugs & Pharmacology Authors: Anne M. Butler, Karynsa Cetin, Rohini K. Hernandez, B. Diane Reams, Robert A. Overman, Jung I. Kim, Bradford R. Hirsch, Amy P. Abernethy, Alexander Liede, M. Alan Brookhart Tags: ORIGINAL REPORT Source Type: research

A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer ...
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a severe stage of the disease with a number of newly discovered treatment options. These therapeutic alternatives including abiraterone acetate, enzalutamide, cabazitaxel, immunotherapy with sipuleucel-T, radiopharmaceuticals and bone...
Source: Iranian Journal of Pharmaceutical Research - December 31, 2017 Category: Drugs & Pharmacology Source Type: research

Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug
This article is protected by copyright. All rights reserved. (Source: Cancer Science)
Source: Cancer Science - December 30, 2017 Category: Cancer & Oncology Authors: Yoshimasa Tanaka, Kaoru Murata ‐Hirai, Masashi Iwasaki, Kenji Matsumoto, Kosuke Hayashi, Asuka Kumagai, Mohanad H. Nada, Hong Wang, Hirohito Kobayashi, Hiroshi Kamitakahara, Haruki Okamura, Tomoharu Sugie, Nagahiro Minato, Masakazu Toi, Craig T. Morita Tags: Original Article Source Type: research

Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis
Investigate role of dose/duration of zoledronic acid (ZOL), a powerful anti-resorptive (pAR), on prevalence of medication-related osteonecrosis of the jaw (MRONJ) in rice rats (Oryzomys palustris), a species with natural susceptibility to food impaction-induced localized periodontitis (FILP). We hypothesize that ZOL induces MRONJ lesions in rice rats with FILP, and that the prevalence of MRONJ rises with increasing dose and duration of ZOL treatment. (Source: Bone)
Source: Bone - December 28, 2017 Category: Orthopaedics Authors: J.G. Messer, J.L. Mendieta Calle, J.M. Jiron, E.J. Castillo, C. Van Poznak, N. Bhattacharyya, D.B. Kimmel, J.I. Aguirre Tags: Full Length Article Source Type: research

Two cases of Gorham-Stout disease with good response to zoledronic acid treatment.
Authors: Brance ML, Castiglioni A, Cóccaro N, Palatnik M Abstract Gorham-Stout disease - also called vanishing bone syndrome - is a rare bone disease characterized by a progressive intra-osseous proliferation of non-neoplastic vascular tissue resulting in massive osteolysis. Here, we report two clinical cases of Gorham-Stout disease. Case 1: a 56-year-old woman with 20 years of history of pain and swell in elbows, ankles and wrist. Then she was diagnosed as systemic lupus erythematosus (SLE) with glomerulonephritis type III. After other pathologies were ruled out Gorham-Stout disease was diagnosed. Intraveno...
Source: Clinical Cases in Mineral and Bone Metabolism - December 22, 2017 Category: Orthopaedics Tags: Clin Cases Miner Bone Metab Source Type: research

An open-label, prospective, observational study of the efficacy of bisphosphonate therapy for painful osteoid osteoma
ConclusionsIn 17/23 patients with painful OO managed conservatively with bisphosphonates, long-term final success was achieved. Bisphosphonates may accelerate the spontaneous healing of OO.Key points•19/23 patients with OO managed with bisphosphonates experienced significant pain relief•Pain relief was sustained in 17/23 patients, mean follow-up of 36 months•CT demonstrated a significant increase in nidus mineralisation•MRI demonstrated a significant decrease in bone marrow oedema•Bisphosphonate therapy may accelerate the spontaneous healing of OO (Source: European Radiology)
Source: European Radiology - December 21, 2017 Category: Radiology Source Type: research

Assessment of geriatric predictors of adherence to Zoledronic acid treatment for osteoporosis: a prospective follow-up study
. (Source: Acta Clinica Belgica)
Source: Acta Clinica Belgica - December 18, 2017 Category: General Medicine Authors: Ilker Tasci Umit Cintosun Umut Safer M. Ilkin Naharci Ergun Bozoglu Aydogan Aydogdu Huseyin Doruk Source Type: research

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries
Conclusion Despite the large proportion of patients receiving BTAs in this study, some patients with BMs are still not receiving early treatment to prevent SREs or to manage pain. Improving physicians’ understanding of the role of BTAs and the importance of early treatment following BM diagnosis has the potential to improve patient care. (Source: Journal of Bone Oncology)
Source: Journal of Bone Oncology - December 16, 2017 Category: Cancer & Oncology Source Type: research